Loading
MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Lung cancer and 1 more.
Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.87, genetic association 0.00, somatic mutation 0.98).
In plain words · MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Lung cancer and 1 more.
MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Lung cancer and 1 more.
Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol.
No product in this corpus aims at MAP3K13 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
First described 1993. Earliest sequence paper UniProt cites for the protein: Schultz S.J. et al, Cell Growth Differ, 1993, "Identification of 21 novel human protein kinases, including 3 members of a family related to the cell cycle regulator nimA of Aspergillus nidulans". Source.
Sources: HGNC HGNC:6852 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O43283 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000073803 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: melanoma 0.55, skin cancer 0.55, breast cancer 0.53, lung cancer 0.51 (GraphQL API, CC0))
Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B. Location: Cytoplasm; Membrane (UniProt). Locus 3q27.2 (HGNC).
Query for this target: (TITLE:"MAP3K13" OR ABSTRACT:"MAP3K13" OR TITLE:"mitogen-activated protein kinase kinase kinase 13" OR ABSTRACT:"mitogen-activated protein kinase kinase kinase 13" OR TITLE:"Mitogen-activated protein kinase kinase kinase 13" OR ABSTRACT:"Mitogen-activated protein kinase kinase kinase 13" OR TITLE:"MEKK13" OR ABSTRACT:"MEKK13") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAP3K13, not a curated reading list.